Dr.RenalNash said:

mona_PHX said: ...compounded vs brand cost and coverage...

This is where I part company with the consensus forming above. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

mona_PHX said:

Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…

Telehealth prescriber review for cost and coverage: I've used 2 different telehealth platforms to get my GLP-1 prescription. Comparison:

I settled on the one that required labs — it shows they care about safety, not just prescribing volume.

DebRD_ATL said:

The affordability discussion here usually stops at individual tactics.

DebRD_ATL said:

...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

1. Document medical necessity (BMI, comorbidities, failed alternatives)
2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
4. Request peer-to-peer review between your doctor and the plan's medical director
5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

A narrower follow-up, since the general answer is now clear:

What would you measure differently if you were starting again?

OP back with an update, since a thread like this is useless without one.

Update: approved on the third attempt after a peer-to-peer. Nothing about my case changed; only who was doing the talking.